HKPD

EFFECT - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

F-1 - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the "Notification Letter") dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the min

6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

20-F - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

NT 20-F - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an

6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ:HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced the closing of its initial public offering (the "Offering") of an aggregate of 1,403,685 ordinary shares, par value $0.001 per share (the "Ordinary Shares") at a public offering price of US$4.00 per share of which 1,000,000 Ordinary Shares were offered by the Company, and 403,685 Ordinary Shares were offered by certain selling shareholders of the Company. Hong Kong Pharma did not receive any proceeds from the sal